



SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

RENOUNCEABLE NON-UNDERWRITTEN RIGHTS CUM WARRANTS ISSUE

- RECEIPT OF LISTING AND QUOTATION NOTICE FROM THE SGX-ST

Unless otherwise defined or the context otherwise requires, all capitalised terms used herein bear the same meanings as in the Announcements (as defined below).

1. INTRODUCTION

The Board of Directors (the “**Board**”) of Singapore Institute of Advanced Medicine Holdings Ltd. (the “**Company**”, together with its subsidiaries, collectively, the “**Group**”) refers to the Company’s announcements dated 30 October 2025, 13 February 2026 and 22 April 2026 (collectively, the “**Announcements**”) in relation to, *inter alia*, the renounceable non-underwritten rights cum warrants issue of up to 492,597,856 new ordinary shares in the capital of the Company (“**Rights Shares**”) at an issue price of S\$0.031 for each Rights Share, with up to 492,597,856 free detachable warrants (“**Warrants**”), each Warrant carrying the right to subscribe for one (1) new Share (“**Warrant Share**”) at an exercise price of S\$0.050 for each Warrant Share, on the basis of two (2) Rights Shares with two (2) free Warrants for every five (5) existing Shares held by the Shareholders as at a date and time to be determined by the Directors for the purpose of determining the Shareholders’ entitlement, fractional entitlements to be disregarded (the “**Rights cum Warrants Issue**”).

2. RECEIPT OF LISTING AND QUOTATION NOTICE

The Board wishes to announce that the Company has, on 11 May 2026, received the listing and quotation notice (the “**LQN**”) from the SGX-ST for the listing of and quotation for the following on the Catalist of the SGX-ST:

- (i) up to 492,597,856 Rights Shares to be issued by the Company at an issue price of S\$0.031 for each Rights Share;
- (ii) up to 492,597,856 Warrants to be issued by the Company, each Warrant carrying the right to subscribe for one Warrant Share at an exercise price of S\$0.050 for each Warrant Share; and
- (iii) up to 492,597,856 Warrant Shares to be issued by the Company upon the exercise of such Warrants,

pursuant to the Rights cum Warrants Issue, subject to the following conditions:

- (i) Compliance with the SGX-ST’s listing requirements; and
- (ii) Submission of a confirmation that a sufficient spread in the Warrants, as required under Rule 826 of the Catalist Rules, is complied with.

The LQN issued by the SGX-ST for the dealing in and the listing of and quotation for the Rights Shares, the Warrants and the Warrant Shares on the Catalist is not to be taken as an indication of the merits of the Rights cum Warrants Issue, the Rights Shares, the Warrants, the Warrant Shares, the Company, its subsidiaries and its securities.

3. FURTHER ANNOUNCEMENTS

The Company will issue an Offer Information Statement in relation to the Rights cum Warrants Issue, setting out, *inter alia*, the terms and conditions of the Rights cum Warrants Issue and the Warrants. The Offer Information Statement will be lodged with the SGX-ST acting as agent on behalf of the Monetary Authority of Singapore and made available electronically to Shareholders in due course.

The Company will make further announcements in relation to the Rights cum Warrants Issue, as and when required.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
12 May 2026

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.